Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 79 of 1402 for:    survival | Neuroendocrine Tumors

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02743741
Recruitment Status : Recruiting
First Posted : April 19, 2016
Last Update Posted : May 12, 2020
Sponsor:
Collaborators:
Ozmosis Research Inc.
Cancer Care Ontario
Canadian Molecular Imaging Probe Consortium
Information provided by (Responsible Party):
University Health Network, Toronto

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : January 2024